NASDAQ:CADL Candel Therapeutics (CADL) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CADL Stock Alerts $5.91 +0.37 (+6.68%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$5.46▼$5.9850-Day Range$1.40▼$7.2852-Week Range$0.66▼$11.40Volume456,083 shsAverage Volume4.27 million shsMarket Capitalization$173.46 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Candel Therapeutics alerts: Email Address Candel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.1% Upside$11.00 Price TargetShort InterestHealthy1.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.43 out of 5 starsMedical Sector687th out of 909 stocksBiological Products, Except Diagnostic Industry118th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingCandel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCandel Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.03% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Candel Therapeutics has recently increased by 9.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCandel Therapeutics does not currently pay a dividend.Dividend GrowthCandel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CADL. Previous Next 1.1 News and Social Media Coverage Search Interest49 people have searched for CADL on MarketBeat in the last 30 days. This is an increase of 4,800% compared to the previous 30 days.MarketBeat Follows20 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Candel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders44.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.93% of the stock of Candel Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Candel Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Candel Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCandel Therapeutics has a P/B Ratio of 13.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Candel Therapeutics Stock (NASDAQ:CADL)Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.Read More CADL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CADL Stock News HeadlinesApril 5, 2024 | marketbeat.comUnusually High Volume Points to Upside in These StocksIf investing were easy, everybody would do it, and we would all be rich. But that isn't the case.April 5, 2024 | marketbeat.comUnusually High Volume Points to Upside in These StocksUnusually high volume is often a signal of higher price to come; this is a look at three stocks with recent volume spikes and a reason for the price to advance.April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 15, 2024 | seekingalpha.comCandel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic CancerApril 11, 2024 | markets.businessinsider.comCandel Therapeutics' CAN-2409 For Pancreatic Cancer Gets FDA Orphan Drug Designation; Stock UpApril 11, 2024 | markets.businessinsider.comWhy Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionApril 11, 2024 | marketwatch.comCandel Therapeutics Shares Leap Premarket on FDA Orphan-Drug DesignationApril 11, 2024 | globenewswire.comCandel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 9, 2024 | globenewswire.comCandel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsApril 6, 2024 | finance.yahoo.comRetail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewardedApril 5, 2024 | benzinga.comWhat's Going On With Candel Therapeutics Stock On Friday?April 5, 2024 | msn.comCandel Therapeutics stock jumps as pancreatic cancer treatment shows promiseApril 4, 2024 | msn.comWhy Allurion Technologies Stock Is Racing HigherApril 4, 2024 | investing.comAfter-hours movers: SoFi Technologies, GameStop, and moreApril 4, 2024 | marketwatch.comCandel Therapeutics Shares Hit 52-Week High After Positive Trial DataApril 4, 2024 | markets.businessinsider.comCandel's CAN-2409 Shows Positive Trial Results In Non-Metastatic Pancreatic Cancer; Stock UpApril 4, 2024 | finance.yahoo.comAfter Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer StudyApril 4, 2024 | globenewswire.comCandel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerApril 1, 2024 | msn.comMicro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor ImmunotherapyMarch 28, 2024 | globenewswire.comCandel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaMarch 28, 2024 | investorplace.comCADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023March 28, 2024 | benzinga.comRecap: Candel Therapeutics Q4 EarningsMarch 28, 2024 | globenewswire.comCandel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsMarch 5, 2024 | globenewswire.comCandel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateFebruary 21, 2024 | benzinga.comCandel Therapeutics Stock (NASDAQ:CADL), Short Interest ReportFebruary 13, 2024 | markets.businessinsider.comCandel's Can-3110 Receives FDA Fast Track DesignationSee More Headlines Receive CADL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CADL CUSIPN/A CIK1841387 Webwww.candeltx.com Phone617-916-5445FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+86.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,940,000.00 Net MarginsN/A Pretax Margin-102,990.34% Return on Equity-142.91% Return on Assets-69.87% Debt Debt-to-Equity Ratio0.97 Current Ratio2.59 Quick Ratio2.59 Sales & Book Value Annual Sales$120,000.00 Price / Sales1,445.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book13.43Miscellaneous Outstanding Shares29,350,000Free Float16,258,000Market Cap$173.46 million OptionableOptionable Beta0.92 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Paul-Peter Tak FMEDSCI (Age 63)M.D., Ph.D., President, CEO & Director Comp: $1.16MDr. Estuardo Aguilar-Cordova Inf. (Age 65)M.D., Ph.D., Founder & Director Comp: $35.08kDr. Seshu Tyagarajan Ph.D. (Age 57)Chief Technical & Development Officer Comp: $335.27kDr. Francesca Barone M.D. (Age 46)Ph.D., Chief Scientific Officer Comp: $518.91kMr. Charles Schoch (Age 39)Interim CFO, VP of Finance & Corporate Controller Ms. Ileen B. WinickChief People OfficerMs. Susan Stewart J.D. (Age 62)L.L.M., Chief Regulatory Officer Dr. William Garrett Nichols M.D. (Age 55)M.S., Chief Medical Officer More ExecutivesKey CompetitorsKodiak SciencesNASDAQ:KODCompugenNASDAQ:CGENGenfitNASDAQ:GNFT10X Capital Venture Acquisition Corp. IIINYSE:VCXBINmune BioNASDAQ:INMBView All CompetitorsInstitutional OwnershipBaystate Wealth Management LLCSold 20,400 shares on 1/29/2024Ownership: 0.266%View All Institutional Transactions CADL Stock Analysis - Frequently Asked Questions Should I buy or sell Candel Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Candel Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CADL shares. View CADL analyst ratings or view top-rated stocks. What is Candel Therapeutics' stock price target for 2024? 1 analysts have issued 1 year target prices for Candel Therapeutics' shares. Their CADL share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price. View analysts price targets for CADL or view top-rated stocks among Wall Street analysts. How have CADL shares performed in 2024? Candel Therapeutics' stock was trading at $1.47 on January 1st, 2024. Since then, CADL shares have increased by 302.0% and is now trading at $5.91. View the best growth stocks for 2024 here. Are investors shorting Candel Therapeutics? Candel Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 160,900 shares, an increase of 9.2% from the March 15th total of 147,300 shares. Based on an average trading volume of 3,880,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.0% of the company's stock are sold short. View Candel Therapeutics' Short Interest. When is Candel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CADL earnings forecast. How were Candel Therapeutics' earnings last quarter? Candel Therapeutics, Inc. (NASDAQ:CADL) issued its quarterly earnings data on Thursday, March, 28th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.22. When did Candel Therapeutics IPO? Candel Therapeutics (CADL) raised $72 million in an initial public offering on Tuesday, July 27th 2021. The company issued 9,000,000 shares at a price of $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. How do I buy shares of Candel Therapeutics? Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CADL) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
